Analyst Price Targets — ANNX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 12, 2026 9:12 am | — | Goldman Sachs | $7.00 | $5.68 | TheFly | Annexon initiated with a Neutral at Goldman Sachs |
| December 23, 2025 9:30 am | Daniil Gataulin | Chardan Capital | $16.00 | $5.19 | TheFly | Annexon initiated with a Buy at Chardan |
| June 5, 2024 5:54 am | Derek Archila | Wells Fargo | $14.00 | $5.99 | StreetInsider | Annexon Biosciences (ANNX) PT Raised to $14 at Wells Fargo |
| May 15, 2024 5:14 am | Derek Archila | Wells Fargo | $10.00 | $4.82 | StreetInsider | Annexon Biosciences (ANNX) PT Lowered to $10 at Wells Fargo |
| April 1, 2024 5:50 am | Derek Archila | Wells Fargo | $12.00 | $7.17 | StreetInsider | Wells Fargo Adds Annexon Biosciences (ANNX) to Q2 '24 Tactical Idea List |
Latest News for ANNX
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity…
BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced an oral presentation on the neuroprotective effect of vonaprument at the American Society of Retina Specialists (ASRS) 44th Annual Scientific…
Annexon remains a high-risk/high-reward Buy, driven by two near-term blockbuster therapies, notably tanruprubart for Guillain-Barré syndrome (GBS). Tanruprubart achieved highly significant Phase 3 results, with a 2.4-fold GBS-DS improvement versus placebo and strong safety, positioning it for standard-of-care status. Regulatory filings are underway: MAA was submitted to EMA, with FDA BLA planned for 2026, supported…
BRISBANE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity…
Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANNX.
U.S. House Trading
No House trades found for ANNX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.